This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System
by Zacks Equity Research
Stereotaxis stock gains as Erasmus Medical adopts Genesis robotic system, marking a milestone in cardiac arrhythmia care.
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Stryker Expands R&D Facility in India to Boost Medtech Innovation
by Zacks Equity Research
SYK expands its Bangalore R&D hub to accelerate robotics, AI and digital health innovation while deepening ties with India's talent pool.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
by Zacks Equity Research
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
Reasons to Retain Cooper Companies Stock in Your Portfolio for Now
by Zacks Equity Research
COO's premium lens strategy, MiSight myopia leadership, and fertility portfolio fuel long-term growth despite near-term headwinds.
SGHT Shares Rise on Meta-Analysis Showing OMNI's Long-Term Benefits
by Zacks Equity Research
Sight Sciences highlights a new meta-analysis showing OMNI delivers lasting safety, efficacy and economic value in glaucoma treatment.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY sees strong order momentum, APAC growth and CyberKnife demand, but soft product sales and regional headwinds cloud near-term gains.
SYK Partners With Siemens Healthineers to Boost Stroke, Aneurysm Care
by Zacks Equity Research
Stryker teams with Siemens Healthineers to develop a robotic ecosystem aimed at advancing stroke and aneurysm care.
Avanos Medical Buys Nexus Medical to Bolster Critical Care Portfolio
by Zacks Equity Research
AVNS acquires Nexus Medical, adding its TKO connector to expand critical care offerings and drive immediate revenue and earnings growth.